Allergen immunotherapy, routes of administration and cytokine networks: An update

Immunotherapy

Volumn 6, Issue 6, 2014, Pages 775-786

  Cuppari, Caterina ^a   Leonardi, Salvatore ^b   Manti, Sara ^a   Filippelli, Martina ^b   Alterio, Tommaso ^a   Spicuzza, Lucia ^b   Rigoli, Luciana ^a   Arrigo, Teresa ^a   Lougaris, Vassilios ^c   Salpietro, Carmelo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

cytokine network; immunotherapy; intradermal route; intralymphatic route; route of administration; subcutaneous route; sublingual route

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 9; TRANSFORMING GROWTH FACTOR BETA;

B LYMPHOCYTE; BASOPHIL; CYTOKINE PRODUCTION; DENDRITIC CELL; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFLAMMATION; MAST CELL; MONOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; BIOLOGICAL MODEL; DESENSITIZATION; DRUG ADMINISTRATION ROUTE; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ALLERGENS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 84904673327     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.47     Document Type: Review

References (123)

1. Bousquet J, Lockey RF, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53, 1-42 (1998).
2. La Rosa M, Lionetti E, Leonardi S et al. Specifc immunotherapy in children: the evidence. Int. J. Immunopathol. Pharmacol. 24, 69-78 (2011).
3. Bacharier LB, Boner A, Carlsen KH et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 63, 5-34 (2008).
4. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 11, 586-593 (2011).
5. Frew AJ. How does sublingual immunotherapy work? J. Allergy Clin. Immunol. 120, 533-536 (2007).
6. Miraglia Del Giudice M, Marseglia A, Leonardi S et al. Allergic rhinitis and quality of life in children. Int. J. Immunopathol. Pharmacol. 24, 25-28 (2011).
7. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 8, CD001186 (2010).
8. Calderon MA, Alves B, Jacobson M et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. 1, CD001936 (2007).
9. Radulovic S, Calderon MA, Wilson D et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 12, CD002893 (2010).
10. Vitaliti G, Leonardi S, Miraglia Del Giudice M et al. Mucosal immunity and sublingual immunotherapy in respiratory disorders. J. Biol. Regul. Homeost. Agents 26, 85-93 (2012).
11. Broide DH. Immunomodulation of allergic disease. Annu. Rev. Med. 60, 279-291(2009).
12. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy J. Allergy Clin. Immunol. 111, 437-448 (2003).
13. Marogna M, Padolini I, Assolo A et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical effcacy and more. Allergy 59, 1205-1210 (2004).
14. Ciprandi G, Cadario G, Di Gioacchino GM et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc. 31, 227-231 (2010).
15. Di Bona D, Plaia A, Leto-Barone MS et al. Effcacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J. Allergy Clin. Immunol. 130, 1097-1107 (2012).
16. Khinchi MS, Poulsen LK, Carat F et al. Clinical effcacy of sublingual and subcutaneous birch pollen allergen-specifc immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59, 45-53 (2004).
17. Dretzke J, Meadows A, Novielli N et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J. Allergy Clin. Immunol. 131, 1361-1366 (2013).
18. DaVeiga SP, Liu X, Caruso K et al. Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment. Ann. Allergy Asthma Immunol. 106, 533-537 (2011).
19. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum. Vaccin. Immunother. 8, 1499-1512 (2012).
20. Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, effcacy and mode of action. Immunotherapy 4, 201-212 (2012).
21. Rigoli L, Briuglia S, Caimmi S et al. Gene-environment interaction in childhood asthma. Int. J. Immunopathol. Pharmacol. 24, 41-47 (2011).
22. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplifed? Nat. Rev. Immunol. 10, 225-235 (2010).
23. Urra JM, Feo Brito F, Carrasco P et al. Allergen stimulation induces simultaneous production of type 2 helper T cells and regulatory cytokines in patients with pollen allergy. J. Investig. Allergol. Clin. Immunol. 23(1), 54-55 (2013).
24. Suurmond J, Stoop JN, Rivellese F et al. Activation of human basophils by combined toll-like receptor-and FceRI-triggering can promote Th2 skewing of naive T helper cells. Eur. J. Immunol. 10, 1002 (2013).
25. Siracusa MC, Kim BS, Spergel JM et al. Basophils and allergic infammation. J. Allergy Clin. Immunol. 132(4), 789-801 (2013).
26. Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 117, 418-425 (2006).
27. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family Nat. Rev. Immunol. 10, 103-110 (2010).
28. Leonardi S, Vitaliti G, Marseglia GL et al. Function of the airway epithelium in asthma. J. Biol. Regul. Homeost. Agents 26, 41-48 (2012).
29. Liu J, Harberts E, Tammaro A et al. IL-9 regulates allergen-specifc Th1 responses in allergic contact dermatitis. J. Invest. Dermatol. doi:10.1038/jid.2014.61 (2014) (Epub ahead of print).
30. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in the big picture of immunology. J. Allergy Clin. Immunol. 120, 247-254 (2007).
31. Lloyd C M, Hawrylowicz CM. Regulatory T cells in asthma. Immunity 31, 438-449 (2009).
32. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
33. Salpietro C, Rigoli L, Miraglia Del Giudice M et al. TLR2 and TLR4 gene polymorphisms and atopic dermatitis in Italian children: a multicenter study. Int. J. Immunopathol. Pharmacol. 24, 33-40 (2011).
34. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132 (2005).
35. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue infammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141(2005).
36. Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur. J. Immunol. 42(9), 2274-2284 (2012).
37. Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB et al. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and infammatory disorders. BioDrugs 27(5), 439-452 (2013).
38. Robinson KM, Manni ML, Biswas PS et al. Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders. Curr. Allergy Asthma Rep. 13(6), 587-595 (2013).
39. Hashimoto T, Akiyama K, Kobayashi N et al. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int. Arch. Allergy Immunol. 137, 51-54 (2005).
40. Li CW, Lu HG, Chen de H et al. In vivo and in vitro studies of Th17 response to specifc immunotherapy in house dust mite-induced allergic rhinitis patients. PLoS One 9(3), e91950 (2014).
41. Ciprandi G, Filaci G, Battaglia F et al. Peripheral Th-17 cells in allergic rhinitis: new evidence. Internat. Immunopharmacol. 10, 226-229 (2010).
42. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
43. Ciprandi G, Cuppari C, Salpietro A et al. Serum IL-23 in asthmatic children. J. Biol. Regul. Homeost. Agents 26, 53-61 (2012).
44. Ciprandi G, Cuppari C, Salpietro C. Serum IL-23: a surrogate biomarker for asthma? Clin. Exp. Allergy 42, 1416-1417 (2012).
45. Ciprandi G, Cuppari C, Salpietro AM et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int. Arch. Allergy Immunol. 159, 183-186 (2012).
46. Akdis M, Burgler S, Crameri R et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol 127, 701-721 (2011).
47. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234 (2006).
48. Vazquez-Tello A, Halwani R, Li R et al. IL-17A a nd IL-17F expression in B lymphocytes. Int. Arch. Allergy Immunol. 157(4), 406-416 (2012).
49. Suárez-Fueyo A, Ramos T, Galán A et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J. Allergy Clin. Immunol. 133(1), 130-138 (2014).
50. Wambre E, DeLong JH, James EA et al. Differentiation stage determines pathologic and protective allergen-specifc CD4+ T-cell outcomes during specifc immunotherapy. J. Allergy Clin. Immunol. 129(2), 544-551 (2012).
51. Suárez-Fueyo A, Ramos T, Galán A et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J. Allergy Clin. Immunol. 133(1), 130-138 (2014).
52. Li Y, Li P. The serum level transformation of IFN-gamma, IL-4 and IgE before and after SIT in patients with allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 27(8), 397-399 (2013).
53. Ciprandi G, De Amici M, Marseglia GL. Serum IL-9 levels and sublingual immunotherapy: preliminary report. J. Biol. Regul. Homeost. Agents 25(2), 295-297 (2011).
54. Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells andmonocytes. J. Immunol. 155, 1079-1090 (1995).
55. Trautmann A, Altznauer F, Akdis M et al. The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J. Invest. Dermatol. 117, 927-934 (2001).
56. Yamanaka K, Nakanishi T, Watanabe J et al. Continuous high-dose antigen exposure preferentially induces IL-10, but intermittent antigen exposure induces IL-4. Dermatol. 23(1), 63-65 (2014).
57. Enk AH, Saloga J, Becker D et al. Induction of hapten-specifc tolerance by interleukin 10 in vivo. J. Exp. Med. 179, 1397-1402 (1994).
58. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. 179, 493-502 (1994).
59. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specifc Immunotherapy FASEB J. 13, 603-609 (1999).
60. Akdis CA, Blesken T, Akdis M et al. Role of IL-10 in specifc immunotherapy. J. Clin. Invest. 102, 98-106 (1998).
61. Mekala DJ, Alli RS, Geiger TL et al. IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+ CD25+ T lymphocytes. Proc. Natl Acad. Sci. USA 102, 11817-11822 (2005).
62. Yang X, Wang S, Fan Y et al. IL-10 defciency prevents IL-5 overproduction and eosinophilic infammation in a murine model of asthma-like reaction. Eur. J. Immunol. 30, 382-391 (2000).
63. Makela MJ, Kanehiro A, Borish L et al. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary infammation after allergic sensitization. Proc. Natl Acad. Sci. USA 97, 6007-6012 (2000).
64. Ciprandi G, De Amici M, Murdaca G et al. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy 64, 1375-1378 (2009).
65. Qiu Q, Lu H, Lu C et al. Variations in TGF-beta, IL-10, and IL-17 after specifc immunotherapy and correlations with symptoms in patients with allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 22 (4), 311-312 (2012).
66. Collison LW, Chaturvedi V, Henderson AL et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11(12), 1093-1101 (2010).
67. Chaturvedi V, Collison LW, Guy CS et al. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J. Immunol. 186, 6661-6666 (2011).
68. Whitehead GS, Wilson RH, Nakano K et al. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129(1), 207-215 (2012).
69. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell. Biol. 1, 169-178 (2000).
70. Taylor A, Verhagen J, Blaser K et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-b: the role of T regulatory cells. Immunology 117, 433-442 (2006).
71. Ciprandi G, De Amici M, Tosca MA et al. Sublingual immunotherapy affects specifc antibody and TGF-beta serum levels in patients with allergic rhinitis. Int. J. Immunopathol. Pharmacol. 22(4), 1089-1096 (2009).
72. Boghdadi G, Marei A, Ali A et al. Immunological markers in allergic rhinitis patients treated with date palm immunotherapy. Infamm. Res. 61(7), 719-724 (2012).
73. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin. Exp. Allergy 38(7), 1074-1088 (2008).
74. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? Curr. Opin. Allergy Clin. Immunol. 12(6), 640-647 (2012).
75. Akdis M, Akdis CA. Mechanisms of allergen-specifc immunotherapy J. Allergy Clin. Immunol. 119, 780-791 (2007).
76. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specifc immunotherapy. Nat. Rev. Immunol. 6, 761-771 (2006).
77. Hamid QA, Schotman E, Jacobson MR et al. Increases in IL-12 messenger RNA1 cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol. 99, 254-260 (1997).
78. Maggi E. T cell responses induced by allergen-specifc immunotherapy Clin. Exp. Immunol. 161, 10-18 (2010).
79. Meiler F, Klunker S. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 63, 1455-1463 (2008).
80. Tversky JR, Bieneman AP, Chichester KL et al. Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin. Exp. Allergy 40, 94-102 (2010).
81. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121, 1120-1125 (2008).
82. Pilette C, Nouri-Aria KT, Jacobson MR et al. Grass pollen immunotherapy induces an allergen-specifc IgA2 antibody response associated with mucosal TGF-beta expression. J. Immunol. 178, 4658-4666 (2007).
83. Moingeon P, Batard T, Fadel R et al. Immune mechanisms of allergen-specifc sublingual Immunotherapy Allergy 61, 151-165 (2006).
84. Smarr CB, Bryce PJ, Miller SD. Antigen-specifc tolerance in immunotherapy of Th2 associated allergic diseases. Crit. Rev. Immunol. 33(5), 389-414 (2013).
85. Soyer OU, Akdis M, Ring J et al. Mechanisms of peripheral tolerance to allergens. Allergy 68(2), 161-170 (2013).
86. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specifc immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy 40, 598-606 (2010).
87. Bohle B, Kinaciyan T, Gerstmayr M et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergenspecifc T-cell tolerance, and immune deviation. J. Allergy Clin. Immunol. 120, 707-713 (2007).
88. Fujimura T, Yonekura S, Taniguchi Y et al. The induced regulatory T cell level, defned as the proportion of IL-10Foxp3(+) cells among CD25(+)CD4(+) leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int. Arch. Allergy Immunol. 153, 378-387 (2010).
89. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J. Allergy Clin. Immunol. 116, 961-968 (2005).
90. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specifc immunotherapy Eur. J. Immunol. 33, 1205-1214 (2003).
91. Radulovic S, Jacobson MR, Durham SR et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol. 121, 1467-1472 (2008).
92. de Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209-1220 (1991).
93. Zhang L, Yi H, Xia XP et al. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity 39 (4), 269-276 (2006).
94. Liu Y, Zhang P, Li J et al. A critical function for TGF-beta signaling in the development of natural CD4 + CD25 + Foxp3+ regulatory T cells. Nat. Immunol. 9, 632-640 (2008).
95. Wachholz PA, Durham SR. Induction of blocking IgG antibodies during immunotherapy. Clin. Exp. Allergy 33, 1171-1174 (2003).
96. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr. Opin. Allergy Clin. Immunol. 4, 313-318 (2004).
97. Till SJ, Francis JN, Nouri-Aria K et al. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113, 1025-1034 (2004).
98. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 19, 281-286 (2007).
99. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against infuenza. N. Engl. J. Med. 351, 2286-2294 (2004).
100. Permpalung N, Wongrakpanich S, Korpaisarn S et al. Trend of human rabies prophylaxis in developing countries: toward optimal rabies immunization. Vaccine 31(38), 4079-4083 (2013).
101. Tameris MD, Hatherill M, Landry BS et al. Safety and effcacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled Phase 2b trial. Lancet 381(9871), 1021-1028 (2013).
102. Koblin BA, Casapia M, Morgan C et al. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One 6(9), e24517 (2011).
103. Leonardi S, Del Giudice MM, Spicuzza L et al. Hepatitis B vaccine administered by intradermal route in patients with celiac disease unresponsive to the intramuscular vaccination schedule: a pilot study. Am. J. Gastroenterol. 105(9), 2117-2119 (2010).
104. Leonardi S, Praticò AD, Lionetti E et al. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J. Gastroenterol. 18(40), 5729-5733 (2012).
105. Nestle FO, Di Meglio P, Qin JZ et al. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9, 679-691 (2009).
106. Swamy M, Jamora C, Havran W et al. Epithelial decision makers: in search of the 'epimmunome'. Nat. Immunol. 11, 656-665 (2010).
107. Ueno H, Schmitt N, Klechevsky E et al. Harnessing human dendritic cell subsets for medicine. Immunol. Rev. 234, 199-212 (2010).
108. Johansen P, von Moos S, Mohanan D et al. New routes for allergen immunotherapy. Hum. Vaccin. Immunother. 8, 1525-1533 (2012).
109. Kissenpfennig A, Henri S, Dubois B et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643-654. (2005).
110. Mondoulet L, Dioszeghy V, Ligouis M et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin. Exp. Allergy 40, 659-667 (2010).
111. Noon L. Prophylactic inoculation against hay fever. Lancet 1, 1572-1573 (1911).
112. Rotiroti G, Shamji M, Durham SR et al. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J. Allergy Clin. Immunol. 130(4), 918-924 (2012).
113. Walker SM, Durham SR, Till SJ et al. Immunotherapy for allergic rhinitis. Clin. Exp. Allergy 41, 1177-1200 (2011).
114. Wambre E, Delong JH, James EA et al. Specifc immunotherapy modifes allergen-specifc CD4(+) T-cell responses in an epitope-dependent manner. J. Allergy Clin. Immunol. 133(3), 872-879 (2014).
115. Slovick A, Douiri A, Kelly J et al. Protocol for a doubleblind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin. Transl. Allergy 3(1), 27 (2013).
116. Agostinis F, Forti S, Di Berardino F et al. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 65, 410-411 (2010).
117. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specifc immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA 105, 17908-17912 (2008).
118. Senti G, Johansen P, Kundig TM et al. Intralymphatic immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9, 537-543 (2009).
119. von Beust BR, Johansen P, Smith KA et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur. J. Immunol. 35, 1869-1876 (2005).
120. Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J. Allergy Clin. Immunol. 129, 1290-1296 (2012).
121. Kündig TM. Immunotherapy concepts under investigation. Allergy 66(95), 60-62 (2011).
122. Witten M, Malling HJ, Blom L et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J. Allergy Clin. Immunol. 132(5), 1248-1252 (2013).
123. Alvarez-Cuesta E, Bousquet J, Canonica GW et al. Standards for practical allergen-specifc immunotherapy. Allergy 61, 1-20 (2006).